Coeliac, HLA DQ2 and HLA-DQ8 Genotyping

HLA-DQ2 and HLA-DQ8 genotyping is a genetic test that identifies whether you carry specific immune system genes strongly associated with coeliac disease. These genes are part of the human leukocyte antigen (HLA) system, which helps your immune system distinguish between the body's own proteins and foreign substances, including food components.

In people with coeliac disease, the HLA-DQ2 or HLA-DQ8 molecules bind to fragments of gluten (gluten peptides) and present them to immune cells in a way that mistakenly triggers an inflammatory response, damaging the lining of the small intestine.

What the genes mean—and don't mean

Approximately 30–40% of the general population carries HLA-DQ2 and/or HLA-DQ8, yet only about 3% of gene carriers actually develop coeliac disease. This means these genes create susceptibility, not certainty. However, their absence is highly informative: individuals who carry neither HLA-DQ2 nor HLA-DQ8 have less than 1% chance of developing coeliac disease, effectively ruling it out in most cases.

Why genotyping is useful

HLA genes are inherited and remain unchanged throughout life. Unlike coeliac antibody tests, which can become negative after removing gluten from the diet or may fluctuate with illness or age, genetic testing provides a stable, lifetime result.

This makes HLA genotyping particularly valuable in several situations:

• When someone has already started a gluten-free diet before testing, making antibody tests unreliable

• When biopsy results are inconclusive or borderline

• In family members of people with coeliac disease who want to assess their own risk

• When investigating unexplained symptoms such as persistent nutritional deficiencies, chronic fatigue, or digestive issues where coeliac disease remains a possibility

The test won't diagnose coeliac disease on its own, but it can definitively rule it out or confirm that further investigation is warranted.

Coeliac disease is an autoimmune condition in which gluten triggers an immune-driven attack on the lining of the small intestine. This can lead to intestinal damage (villous atrophy), impaired nutrient absorption, chronic inflammation, and a wide range of symptoms affecting digestion, metabolism, hormones, immunity, and overall wellbeing.

Understanding your HLA status matters because it establishes whether coeliac disease is even possible. The presence of HLA-DQ2 or DQ8 genes means that, under certain conditions—namely gluten exposure, immune activation, microbiome imbalance, or environmental triggers—you could develop coeliac disease. The absence of these genes makes coeliac disease extremely unlikely, allowing clinicians to explore other causes of symptoms such as fatigue, bloating, abdominal pain, anaemia, malabsorption, skin conditions, or hormonal disturbances.

Coeliac disease affects more than just digestion. Untreated intestinal inflammation can reduce absorption of iron, calcium, magnesium, zinc, folate, B12, and fat-soluble vitamins, contributing to anaemia, bone loss, infertility, thyroid issues, neurological symptoms, and chronic fatigue. In children, it may impair growth. Understanding genetic susceptibility enables earlier screening and monitoring, especially when symptoms are subtle or inconsistent.

HLA genotyping is also important for people who have started a gluten-free diet before testing. Because coeliac antibody tests rely on gluten exposure to detect a reaction, they may appear normal even when coeliac disease is present. A positive HLA test keeps the diagnosis possible; a negative result rules it out and prevents unnecessary dietary restriction.

In families with coeliac disease, risk increases significantly: first-degree relatives have a 1 in 10 chance of developing the condition. Knowing HLA status helps determine who should undergo regular screening. Genetic testing can also support diagnosis when biopsies are inconclusive or when symptoms persist despite a gluten-free diet.

Genetic markers themselves do not fluctuate—you either carry HLA-DQ2/DQ8 or you do not. However, whether coeliac disease develops depends on additional factors:

Dietary Factors Gluten exposure is essential for triggering autoimmunity in genetically susceptible individuals. The amount, frequency, and timing of gluten intake can influence whether or when symptoms develop.

Lifestyle Factors Stress, sleep disruption, and illness can modify immune activation. Long-term inflammation or viral infections may precipitate autoimmune shifts.

Related Biomarkers Coeliac serology (tTG-IgA, DGP-IgG) reflects active immune response, not genetic risk. Iron studies, folate, vitamin D, B12, and zinc can reveal malabsorption if coeliac disease develops. CRP or ESR may indicate systemic inflammation.

Micronutrient Impacts Even before diagnosis, individuals with genetic risk may show nutrient depletions if intestinal inflammation begins.

Environmental and Microbiome Influences Gut permeability, dysbiosis, and gastrointestinal infections can affect whether gluten triggers autoimmunity. Epigenetic factors—stress, infections, toxins—may influence disease expression in genetically susceptible individuals.

If your results show HLA DQ2 or DQ8 positivity:

1. Understand it as a risk, not a diagnosis. Many carriers never develop coeliac disease.

2. Pair your genetic results with serological testing (e.g., tTG-IgA, DGP-IgG) for a complete picture.

3. If you are symptomatic or have a family history, discuss screening with your clinician.

4. Avoid starting a gluten-free diet without medical guidance as this can interfere with diagnostic accuracy.

5. If both alleles are absent, coeliac disease is effectively excluded, allowing your clinician to investigate other causes of symptoms.

For individuals with coeliac disease or gluten intolerance, some grains are significantly better choices than others. The cornerstone of management is a lifelong, strict gluten-free diet that excludes wheat, rye, and barley. Fortunately, a number of gluten-free grains and pseudo-cereals—such as quinoa, amaranth, buckwheat, millet, and sorghum—offer excellent nutritional value. These grains are naturally rich in protein, fibre, B-complex vitamins, minerals, and healthy unsaturated fats, helping to improve the nutrient density of a gluten-free diet and support overall gut and metabolic health.

Pure, uncontaminated oats are also well tolerated by most people with coeliac disease and can contribute valuable fibre and micronutrients. It is, however, essential to confirm that oats are certified gluten-free to avoid cross-contamination during processing, which is a common source of inadvertent gluten exposure.

When selecting gluten-free foods, whole-grain and minimally processed options should always take priority. Many processed gluten-free products have a higher glycaemic index and lower nutritional quality compared with their whole-food counterparts. To counter common nutrient shortfalls associated with gluten-free diets—particularly fibre, iron, calcium, magnesium, and B-vitamins—it’s best to include a variety of whole gluten-free grains, legumes, nuts, seeds, leafy greens, seafood, and fortified foods.

For everyday practical use, choose certified gluten-free flours and grains, carefully read labels for “may contain gluten” or shared-line warnings, and rotate your grain choices to keep the diet diverse and nutritionally complete. Dishes such as quinoa bowls, buckwheat soba, millet pilafs, and sorghum porridges are simple ways to incorporate variety. If symptoms persist despite dietary vigilance, clinicians may recommend repeating laboratory tests—such as iron studies, vitamin B12 and folate, vitamin D, calcium, or follow-up coeliac serology—to check for hidden deficiencies or ongoing inflammation.

1. Fasano, A., & Catassi, C. (2012). Celiac disease. The New England Journal of Medicine, 367(25), 2419–2426. https://doi.org/10.1056/NEJMcp1113994
   

2. Lammi, A., Arikoski, P., Simell, S., et al. (2015). Antibodies to deamidated gliadin peptide in diagnosis of celiac disease in children. Journal of Pediatric Gastroenterology and Nutrition, 60(5), 626–631. https://doi.org/10.1097/MPG.0000000000000666
   

3. Zingone, F., Norman, G. L., Smecuol, E., et al. (2025). Utilizing both IgA tissue transglutaminase and IgG-deamidated gliadin peptide antibodies offers accurate celiac disease diagnosis without duodenal biopsy. Digestive and Liver Disease, 57(2), 609–615. https://doi.org/10.1016/j.dld.2024.10.010
   

4. Hill, I. D., Fasano, A., Guandalini, S., et al. (2016). NASPGHAN clinical report on the diagnosis and treatment of gluten-related disorders. Journal of Pediatric Gastroenterology and Nutrition, 63(1), 156–165. https://doi.org/10.1097/MPG.0000000000001216
   

5. Mooney, P. D., Wong, S. H., Johnston, A. J., et al. (2015). Increased detection of celiac disease with measurement of deamidated gliadin peptide antibody before endoscopy. Clinical Gastroenterology and Hepatology, 13(7), 1278–1284.e1. https://doi.org/10.1016/j.cgh.2015.01.010
   

6. Leonard, M. M., Lebwohl, B., Rubio-Tapia, A., & Biagi, F. (2021). AGA clinical practice update on the evaluation and management of seronegative enteropathies: Expert review. Gastroenterology, 160(1), 437–444. https://doi.org/10.1053/j.gastro.2020.08.061
   

7. Fasano, M. E., Dametto, E., & D'Alfonso, S. (2015). HLA genotyping: Methods for the identification of the HLA-DQ2 and HLA-DQ8 heterodimers implicated in celiac disease susceptibility. Methods in Molecular Biology, 1326, 79–92. https://doi.org/10.1007/978-1-4939-2839-2_9
   

8. Husby, S., Murray, J. A., & Katzka, D. A. (2019). AGA clinical practice update on diagnosis and monitoring of celiac disease—Changing utility of serology and histologic measures: Expert review. Gastroenterology, 156(4), 885–889. https://doi.org/10.1053/j.gastro.2018.12.010
   

9. Choung, R. S., Mills, J. R., Snyder, M. R., Murray, J. A., & Gandhi, M. J. (2020). Celiac disease risk stratification based on HLA-DQ heterodimer (HLA-DQA1~DQB1) typing in a large cohort of adults with suspected celiac disease. Human Immunology, 81(2–3), 59–64. https://doi.org/10.1016/j.humimm.2020.01.006
   

10. Lionetti, E., Castellaneta, S., Francavilla, R., et al. (2014). Introduction of gluten, HLA status, and the risk of celiac disease in children. The New England Journal of Medicine, 371(14), 1295–1303. https://doi.org/10.1056/NEJMoa1400697